JP2018131450A5 - - Google Patents

Download PDF

Info

Publication number
JP2018131450A5
JP2018131450A5 JP2018083792A JP2018083792A JP2018131450A5 JP 2018131450 A5 JP2018131450 A5 JP 2018131450A5 JP 2018083792 A JP2018083792 A JP 2018083792A JP 2018083792 A JP2018083792 A JP 2018083792A JP 2018131450 A5 JP2018131450 A5 JP 2018131450A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
sulfonylurea
methyl
composition according
metformin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018083792A
Other languages
English (en)
Japanese (ja)
Other versions
JP6811203B2 (ja
JP2018131450A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2018131450A publication Critical patent/JP2018131450A/ja
Publication of JP2018131450A5 publication Critical patent/JP2018131450A5/ja
Application granted granted Critical
Publication of JP6811203B2 publication Critical patent/JP6811203B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018083792A 2008-10-16 2018-04-25 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療 Active JP6811203B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US10591908P 2008-10-16 2008-10-16
EP08166829 2008-10-16
EP08166829.5 2008-10-16
US61/105,919 2008-10-16
EP09167304 2009-08-05
EP09167304.6 2009-08-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016046077A Division JP2016164161A (ja) 2008-10-16 2016-03-09 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020128354A Division JP7174020B2 (ja) 2008-10-16 2020-07-29 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療

Publications (3)

Publication Number Publication Date
JP2018131450A JP2018131450A (ja) 2018-08-23
JP2018131450A5 true JP2018131450A5 (enExample) 2018-10-04
JP6811203B2 JP6811203B2 (ja) 2021-01-13

Family

ID=41426834

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2011531494A Pending JP2012505859A (ja) 2008-10-16 2009-10-15 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
JP2014039772A Active JP6262023B2 (ja) 2008-10-16 2014-02-28 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
JP2016046077A Pending JP2016164161A (ja) 2008-10-16 2016-03-09 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
JP2018083792A Active JP6811203B2 (ja) 2008-10-16 2018-04-25 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
JP2022111237A Pending JP2022125360A (ja) 2008-10-16 2022-07-11 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
JP2024208369A Pending JP2025029032A (ja) 2008-10-16 2024-11-29 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2011531494A Pending JP2012505859A (ja) 2008-10-16 2009-10-15 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
JP2014039772A Active JP6262023B2 (ja) 2008-10-16 2014-02-28 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
JP2016046077A Pending JP2016164161A (ja) 2008-10-16 2016-03-09 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022111237A Pending JP2022125360A (ja) 2008-10-16 2022-07-11 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療
JP2024208369A Pending JP2025029032A (ja) 2008-10-16 2024-11-29 経口又は非経口抗糖尿病薬による治療にもかかわらず不十分な血糖調節の患者の糖尿病の治療

Country Status (20)

Country Link
US (3) US20110275561A1 (enExample)
EP (2) EP3150204A3 (enExample)
JP (6) JP2012505859A (enExample)
KR (6) KR20110066936A (enExample)
CN (3) CN102186466A (enExample)
AR (1) AR073876A1 (enExample)
AU (1) AU2009305419B2 (enExample)
CA (1) CA2738367C (enExample)
CO (1) CO6361917A2 (enExample)
EA (1) EA026810B1 (enExample)
EC (1) ECSP11010971A (enExample)
IL (1) IL211370A0 (enExample)
MA (1) MA32872B1 (enExample)
MX (4) MX2011003774A (enExample)
NZ (2) NZ605207A (enExample)
PE (1) PE20110396A1 (enExample)
TN (1) TN2011000176A1 (enExample)
TW (1) TWI520738B (enExample)
UY (1) UY32177A (enExample)
WO (1) WO2010043688A1 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
BRPI0711558A2 (pt) 2006-05-04 2011-11-08 Boeringer Ingelheim Internat Gmbh polimorfos
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20090938A1 (es) 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
RU2504373C2 (ru) 2008-03-26 2014-01-20 ОРАМЕД Лтд. Способы и композиции для перорального введения протеинов
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
AU2009290911A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
EP2382216A1 (en) 2008-12-23 2011-11-02 Boehringer Ingelheim International GmbH Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
MX339194B (es) 2009-02-13 2016-05-16 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
WO2010092163A2 (en) * 2009-02-13 2010-08-19 Boehringer Ingelheim International Gmbh Antidiabetic medications
JP5789252B2 (ja) * 2009-05-07 2015-10-07 インテリカイン, エルエルシー 複素環式化合物およびその使用
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
EP2566464A1 (en) * 2010-05-05 2013-03-13 Boehringer Ingelheim International GmbH Pharmaceutical formulations comprising pioglitazone and linagliptin
MX341025B (es) 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
PH12012502524A1 (en) * 2010-06-24 2014-02-10 Boehringer Ingelheim Int Diabetes therapy
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AU2016202261B2 (en) * 2010-11-15 2017-11-30 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
EP3517539B1 (en) 2011-07-15 2022-12-14 Boehringer Ingelheim International GmbH Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303554A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体
EP2854812A1 (en) * 2012-05-24 2015-04-08 Boehringer Ingelheim International GmbH A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN104902921A (zh) 2013-01-03 2015-09-09 奥拉姆德有限公司 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
JP2016510795A (ja) * 2013-03-15 2016-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
CN106188058B (zh) * 2015-05-29 2020-11-06 江苏天士力帝益药业有限公司 黄嘌呤衍生物
US20200185063A1 (en) 2016-06-05 2020-06-11 Berg Llc Systems and methods for patient stratification and identification of potential biomarkers
CN109310697A (zh) 2016-06-10 2019-02-05 勃林格殷格翰国际有限公司 利格列汀和二甲双胍的组合
WO2018058109A1 (en) * 2016-09-26 2018-03-29 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
SI1953162T1 (sl) * 2001-02-24 2012-09-28 Boehringer Ingelheim Pharma Ksantinski derivati, njihova priprava in njihova uporaba kot zdravila
US7610153B2 (en) * 2002-02-13 2009-10-27 Virginia Commonwealth University Multi-drug titration and evaluation
CA2496249C (en) * 2002-08-21 2012-01-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
DE10238470A1 (de) * 2002-08-22 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
UY28103A1 (es) * 2002-12-03 2004-06-30 Boehringer Ingelheim Pharma Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
DE60331236D1 (de) * 2003-07-24 2010-03-25 Eswaran Krishnan Iyer Orale zusammensetzungen zur behandlung von diabetes
ATE534404T1 (de) * 2003-10-03 2011-12-15 Takeda Pharmaceutical Dipeptidylpeptidase-iv-inhibitoren zur behandlung von diabetes-patienten mit sekundärversagen durch sulfonylharnstoffe
JP2005126430A (ja) * 2003-10-03 2005-05-19 Takeda Chem Ind Ltd 糖尿病治療剤
AU2005219508B2 (en) * 2004-02-18 2012-02-16 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a DPP inhibitor
WO2005117861A1 (en) * 2004-06-04 2005-12-15 Novartis Ag Use of organic compounds
EP1782832A4 (en) * 2004-08-26 2009-08-26 Takeda Pharmaceutical MEANS FOR THE TREATMENT OF DIABETES
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN101384594A (zh) * 2005-12-23 2009-03-11 诺瓦提斯公司 用作dpp-iv抑制剂的稠合杂环化合物
WO2008017670A1 (en) * 2006-08-08 2008-02-14 Boehringer Ingelheim International Gmbh Pyrrolo [3, 2 -d] pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
PE20090597A1 (es) * 2007-08-16 2009-06-06 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
PE20090938A1 (es) * 2007-08-16 2009-08-08 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo
GB2465132B (en) * 2007-09-21 2012-06-06 Lupin Ltd Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
BRPI0920699A2 (pt) * 2008-10-16 2020-09-01 Boehringer Ingelheim International Gmbh uso de um inibidor de dpp-4 no tratamento de diabetes em pacientes com controle insuficiente da glicemia apesar de terapia com um fármaco antidiabético oral ou não-oral
MX339194B (es) 2009-02-13 2016-05-16 Boehringer Ingelheim Int Composicion farmaceutica que comprende un inhibidor de sglt2, un inhibidor de dpp-iv y opcionalmente otro agente antidiabetico, y usos de la misma.
EA034869B1 (ru) * 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин

Similar Documents

Publication Publication Date Title
JP5077786B2 (ja) 併用医薬
JP4643760B2 (ja) Dpp−iv阻害薬と他の糖尿病治療薬との併用又は組み合せからなる医薬
US20110269750A1 (en) Roflumilast for the treatment of diabetes mellitus
JP2021035998A5 (enExample)
HRP20170022T1 (hr) Farmaceutski sastav koji obuhvaća derivat benzena supstituiran glukopiranozilom
NZ605207A (en) Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug
JP2019517542A5 (enExample)
JP2024515137A (ja) Gpr40アゴニスト及びsglt-2阻害剤を含む医薬組成物
TWI519297B (zh) 使用雙醋瑞因之糖尿病輔助療法
KR100709528B1 (ko) 혈당콘트롤용 의약조성물
US20190060301A1 (en) Tesofensine and metoprolol for treatment of hypertension
Schernthaner et al. Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial
JP2012503598A (ja) 糖尿病治療のための医薬組成物
HK40097553A (en) Pharmaceutical composition comprising gpr40 agonist and sglt-2 inhibitor
HK40094446A (en) Glp-1 dosing regimen
Ábel A new therapy of type 2 diabetes: DPP-4 inhibitors
JP2011105609A (ja) メトホルミンへの付加療法を含む2型糖尿病の治療方法
JP2009513593A (ja) 糖尿病の治療
BR112020026164A2 (pt) terapia antidiabética cardioprotetora e nefroprotetora
Masoodi Traditional Oral Antidiabetic Drugs in Ramadan
KR20110052987A (ko) 메트포르민에 대한 부가적 요법을 포함하는 2형 당뇨병의 치료 방법
Lombard et al. ADA Watch summaries